How and what adverse events are reported and captured in randomized control trials of emollients in the treatment of eczema?
Clinical and Experimental Dermatology · 2023
DOI: 10.1093/ced/llad137 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2023. Verfasst von Elizabeth R Emmett und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gloucestershire NHS Trust, Cheltenham, UK. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Eczema. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Academy of Medical Sciences, INSPIRE, Wellcome Trust.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Emollients are universally recommended for atopic dermatitis/eczema (‘eczema’), to improve the skin barrier and reduce symptoms. However, our knowledge of the frequency and nature of adverse effects associated with their use is limited.
Objectives
We sought to determine how well adverse events are reported in randomized controlled trials (RCTs) of emollients for eczema.
Methods
MEDLINE was searched from inception (1946) to May 2022. Inclusion criteria were RCTs of moisturizers or emollients used as a leave-on treatment (as the intervention or control) in adults or children with eczema. Exclusion criteria were non-RCTs; patients with other diagnoses included; use of emollient as bath additives, soap substitutes or as preventative; and not published in English. References of eligible papers were reviewed for any additional, relevant research. Data were extracted into an Excel spreadsheet and analysed descriptively. An assessment of study quality was carried out using the Joanna Briggs Institute tool for RCTs.
Results
From 369 potential papers, 35 papers (reporting on 34 studies) were included. Most research was conducted in research centres or hospitals (unclear in 34%). In total, 89% reported collecting data on adverse events related to emollient treatment use but the methods used were poorly reported (40% unclear). Four papers used patient questionnaires/diaries. However, it was unclear how and what was collected as only two studies showed the questionnaires used.
Conclusions
Reporting of adverse events related to emollient use in trials of patients with eczema is poor and inconsistent. Agreement should be reached on how and what adverse events should be collected, to standardize reporting across studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Gloucestershire NHS Trust, Cheltenham, UK.
- Bristol Medical School, University of Bristol, Bristol, UK.
- Great Western Hospitals NHS Trust, Swindon, UK.
ORCID-Profile: Elizabeth R Emmett
Förderung
- Academy of Medical Sciences
- INSPIRE
- Wellcome Trust
Zitieren
APA
Emmett, E. R., Allen, M., Crownshaw, S., & Ridd, M. J. (2023). How and what adverse events are reported and captured in randomized control trials of emollients in the treatment of eczema?. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llad137
Vancouver
Emmett ER, Allen M, Crownshaw S, Ridd MJ. How and what adverse events are reported and captured in randomized control trials of emollients in the treatment of eczema?. Clinical and Experimental Dermatology. 2023. doi:10.1093/ced/llad137
BibTeX
@article{Emmett2023,
author = {Emmett, Elizabeth R and Allen, Megan and Crownshaw, Sarah and Ridd, Matthew J},
title = {How and what adverse events are reported and captured in randomized control trials of emollients in the treatment of eczema?},
journal = {Clinical and Experimental Dermatology},
year = {2023},
doi = {10.1093/ced/llad137}
}
EUVIMED